Lexicon Pharma to Cut Around 45% of Workforce; CEO to Depart

Lexicon Pharmaceuticals will focus its efforts on late-stage drug development, which will lead to the loss of 115 jobs.

Jan 13, 2014 at 4:31PM

Lexicon Pharmaceuticals (NASDAQ:LXRX) is narrowing its business focus in an effort that will lead to a substantial reduction in head count, and its CEO will also be departing.

The company announced that it will concentrate its resources on late-stage drug development programs. For the most part, this consists of two treatments it's currently developing -- one for diabetes, and the other for carcinoid syndrome. As a result of this new concentration, around 115 employees will no longer work at the firm. That's roughly 45% of the present workforce.

With these measures, Lexicon says it will reduce its expenses by a net amount of approximately $14 million for the balance of its fiscal 2014 and around $22 million annually going forward.

In the press release announcing the news, the firm quoted CEO Arthur Sands as saying that the new focus "increases Lexicon's financial strength and will enable the company to more effectively advance our key late-stage programs and to prepare for commercialization."

Sands will not stay in his current position. In the press release, the company revealed that he has "indicated his intention to develop a succession plan with the board of directors to identify a new chief executive officer for the next phase of Lexicon's growth." Sands will stay in his position until the board finds his replacement. 

Last month, Lexicon's share price swooned after the company reported disappointing results from its phase 2 study of LX1033, a treatment for irritable bowel syndrome. 

Fool contributor Eric Volkman has no position in Lexicon Pharmaceuticals. Nor does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information